Vertex Pharmaceuticals

Vertex Pharmaceuticals

Biotechnology Research

Boston, MA 404,447 followers

The Science of Possibility

About us

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and have made significant advancements in multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continue to progress clinical and research programs in these diseases. We also have a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where we have deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Our global HQ is in Boston, and we have R&D sites and commercial offices worldwide. Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. We have also earned a spot on TIME Most Influential Companies, TIME Best Inventions, and Fast Company Most Innovative Companies lists. Our research and medicines have received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the Prix Galien, the Scrip Award and the Breakthrough Prize awards.

Website
https://www.vrtx.com/
Industry
Biotechnology Research
Company size
5,001-10,000 employees
Headquarters
Boston, MA
Type
Public Company
Founded
1989
Specialties
cystic fibrosis, alpha-1 antitrypsin deficiency (AATD), APOL1-mediated kidney diseases, sickle cell disease, beta thalassemia, Duchenne muscular dystrophy, and type 1 diabetes mellitus

Locations

Employees at Vertex Pharmaceuticals

Updates

Similar pages

Browse jobs

Stock

VRTX

NASDAQ

20 minutes delay

$397.27

0.63 (0.159%)

Open
395.72
Low
386.49
High
401.31

Data from Refinitiv

See more info on Bing

Funding

Vertex Pharmaceuticals 7 total rounds

Last Round

Post IPO secondary

US$ 1.1M

See more info on crunchbase